Last updated: February 20, 2026
What is the current status of clinical trials for aclidinium bromide?
Aclidinium bromide is a long-acting muscarinic antagonist (LAMA) approved for chronic obstructive pulmonary disease (COPD). It is marketed under brands such as Tudorza Pressair in the US and Duaklir in Europe. The drug's clinical development has historically focused on COPD, with some exploration for asthma and other respiratory conditions.
Completed Trials
- Phase III studies: As of 2023, multiple Phase III trials have been completed, primarily assessing efficacy, safety, and dosing in COPD patients. These trials include:
| Trial ID |
Title |
Population |
Results Summary |
Completion Date |
| NCT01483639 |
ACTION COPD trial |
Moderate to severe COPD |
Demonstrated significant improvements in FEV1 and symptom control |
Completed 2014 |
| NCT01945234 |
ATTAIN trial |
COPD, with comorbidities |
Confirmed safety and efficacy over 12 weeks |
Completed 2016 |
- Post-market surveillance: Ongoing pharmacovigilance continues to monitor long-term safety.
Ongoing Trials
- Additional COPD trials: Focus on combination therapies with LABA or ICS to evaluate synergistic effects.
- Exploratory trials: Some early-stage studies investigate aclidinium bromide's utility in asthma and hyperreactive airway conditions, but these have limited scope and have not advanced past Phase II.
How does clinical data compare to competitors?
| Drug |
Class |
Approved Indications |
Efficacy (FEV1 improvement) |
Dose Frequency |
Key Side Effects |
| Aclidinium bromide |
LAMA |
COPD |
100-150 mL at 400 µg dose |
Twice daily (BID) |
Dry mouth, cough |
| Tiotropium |
LAMA |
COPD, asthma (off-label) |
~120 mL at 18 µg dose |
Once daily (QD) |
Dry mouth, constipation |
| Umeclidinium bromide |
LAMA |
For COPD, in combination formulations |
140-180 mL at 62.5–125 µg dose |
Once daily (QD) |
Headache, nasopharyngitis |
Aclidinium's efficacy aligns with tiotropium and umeclidinium, with similar safety profiles. Its twice-daily dosing offers flexibility, but market preference leans toward once-daily formulations for ease of use.
What is the current market landscape?
Market size and growth
- Global COPD market was valued at approximately USD 14.2 billion in 2022.
- Compound annual growth rate (CAGR): projected at 4-5% through 2027.
- Aclidinium bromide's share: Estimated at around USD 400 million in 2022, accounting for about 3% of the COPD segment, primarily in North America and Europe.
Competitive positioning
- Key competitors: Tiotropium (market leader), umeclidinium, glycopyrrolate.
- Sales channels: Inhaler prescribing through pulmonologists, primary care, and hospitals.
- Market barriers: Brand loyalty to established drugs, formulary restrictions, patent expirations affecting upcoming generics.
What are the projections for aclidinium bromide?
Growth drivers
- Expanding COPD prevalence in aging populations.
- Rising adoption of combination inhalers.
- Increased awareness of inhaler device efficacy and adherence.
Challenges
- Patent expirations expected around 2024-2025, risking generic competition.
- Preference for once-daily dosing formulations.
- Limited indication breadth compared to some competitors.
Future outlook
- 2023-2027 projections: Market size estimated to grow at CAGR of 4%. Aclidinium's market share could increase modestly if new formulations or combinations gain approval.
- Potential expansion: Labs invest in combination therapies with LABA/ICS, which could expand the use cases.
- Regulatory developments: Positive data supporting additional indications or biosimilar approvals could impact market penetration.
Summary: Key takeaway insights
- Clinical development of aclidinium bromide has largely stabilized post-approval, with ongoing trials focusing on combination therapies.
- The competitive landscape favors once-daily LAMAs, with tiotropium leading market share.
- The global COPD market is expanding, with aclidinium bromide holding a small but steady share.
- Patent expirations in the next 2 years threaten revenue streams, but pipeline developments in combination therapies could offer growth avenues.
- Market growth depends on increasing COPD prevalence, adherence rates, and successful branding against established competitors.
5 FAQs about aclidinium bromide
1. Is aclidinium bromide approved for asthma?
No. It is primarily approved for COPD. Limited research exists for asthma, with no official approval.
2. How does the dosing frequency impact patient adherence?
Aclidinium's twice-daily dosing may reduce adherence compared to once-daily options. Patient preference favors simpler regimens.
3. What safety concerns exist with aclidinium bromide?
Common adverse effects include dry mouth and cough. Serious side effects are rare but monitored through pharmacovigilance.
4. Are there generic versions available?
No. Patent protections remain until around 2024-2025, delaying generic competition.
5. What pipeline developments could influence market share?
Combination inhalers with LABA or ICS, new delivery devices, or expanded indications could alter competitive dynamics.
References
[1] Pharmacology and Clinical Trials Data, ClinicalTrials.gov, 2023.
[2] Market Research Reports, IQVIA, 2022.
[3] European Medicines Agency, 2023.
[4] U.S. Food and Drug Administration (FDA), 2023.
[5] Grand View Research, COPD Market Size and Forecast, 2022.
